Travere Therapeutics
TVTX
278 hedge funds and large institutions have $3.9B invested in Travere Therapeutics in 2025 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 90 increasing their positions, 93 reducing their positions, and 35 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
120% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 35
62% more capital invested
Capital invested by funds: $2.41B → $3.9B (+$1.5B)
17% more funds holding
Funds holding: 238 → 278 (+40)
1.18% more ownership
Funds ownership: 113.03% → 114.22% (+1.2%)
7% more call options, than puts
Call options by funds: $111M | Put options by funds: $103M
3% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 93
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$219M |
| 2 |
State Street
Boston,
Massachusetts
|
+$50M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$28.4M |
| 4 |
Goldman Sachs
New York
|
+$19.3M |
| 5 |
Renaissance Technologies
New York
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$119M |
| 2 |
AC
Armistice Capital
New York
|
-$96.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$27.5M |
| 4 |
Jennison Associates
New York
|
-$26.9M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$23.3M |
TVTX Hedge Fund Activity: Q4 2025 in Review
278 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2025, worth a combined $3.9B — up 62% from $2.41B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new TVTX positions and 35 closed out — a net gain of 42 holders — while 90 added to existing stakes and 93 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $219M. The largest seller was Macquarie Group, exiting entirely with an estimated $119M sold.
- 278 institutional investors held Travere Therapeutics (TVTX) as of Q4 2025, up from 238 in Q3 2025.
- Funds reported $3.9B of Travere Therapeutics stock for Q4 2025, up 62% quarter-over-quarter.
- 77 funds opened new Travere Therapeutics positions in Q4 2025 and 35 closed out, a net change of +42 holders.
- The largest Travere Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $219M added.
- The largest Travere Therapeutics seller in Q4 2025 was Macquarie Group, an estimated $119M sold.
Based on aggregated 13F filings for Q4 2025.